Pfizer Inc. and Allergan PLC have terminated "by mutual agreement" their $160bn merger . The decision was driven by new US Treasury Department rules endorsed by President Barack Obama to prevent tax inversion deals that were announced on April 4, 2016.
Pfizer Inc. and Allergan PLC have terminated "by mutual agreement" their $160bn merger . The decision was driven by new US Treasury Department rules endorsed by President Barack Obama to prevent tax inversion deals that were announced on April 4, 2016.
Pfizer says it has agreed to pay Allergan $150m for reimbursement of expenses associated with the transaction. The amount is...
The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.
Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.
While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
The first twice-yearly option for HIV prevention has been approved by the US Food and Drug Administration in an advance that “brings us closer than ever to ending the HIV epidemic,” said CEO Daniel O’Day.
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.
